Search results for "Asunaprevir"

showing 3 items of 3 documents

Daclatasvir-based regimens in HCV cirrhosis: experience from the Italian early access program

2019

AbstractWe reported the efficacy and safety data for daclatasvir (DCV)-based all-oral antiviral therapy in patients treated in the Italian compassionate-use program. 275 patients were included (202 male-73.5%, mean age: 57.4 years, 62 HIV-coinfected, 94 with recurrence of hepatitis C post-OLT). Forty-nine patients (17.8%) had Child-Pugh B, Genotype(G) distribution was: G1a:72 patients (26.2%), G1b:137 (49.8%); G3:40 (14.5%) and G4:26 (9.5%). Patients received DCV with sofosbuvir(SOF) (n = 221, 129 with ribavirin(RBV) or with simeprevir (SMV) or asunaprevir (ASU) (n = 54, 19 with RBV) for up to 24 weeks. Logistic regression was used to identify baseline characteristics associated with sustai…

0301 basic medicineSimeprevirLiver CirrhosisMalePyrrolidinesSofosbuvirSustained Virologic Responselcsh:MedicineSettore MED/05Gastroenterologychemistry.chemical_compound0302 clinical medicineLiver Function TestsINFECTIONMedicinePLUS SOFOSBUVIRlcsh:ScienceSulfonamidesMultidisciplinaryImidazolesValineHepatitis CMiddle AgedTreatment OutcomeItalySAFETYHCVSUSTAINED VIROLOGICAL RESPONSEDrug Therapy CombinationFemaleRIBAVIRINSettore BIO/19 - MICROBIOLOGIA GENERALECHRONIC HEPATITIS-Cmedicine.drugAdultmedicine.medical_specialtyDaclatasvirDrug-Related Side Effects and Adverse ReactionsAntiviral AgentsArticle03 medical and health sciencesInternal medicineHumansAgedADVANCED LIVER-DISEASEbusiness.industryRibavirinVIRUS GENOTYPE 3lcsh:RHepatitis C ChronicHCV HIV Daclatasvirmedicine.diseaseIsoquinolinesEFFICACYRegimen030104 developmental biologychemistryAsunaprevirlcsh:QLiver functionCarbamatesSofosbuvirbusiness030217 neurology & neurosurgeryScientific Reports
researchProduct

Raltegravir Pharmacokinetics in Patients on Asunaprevir-Daclatasvir.

2015

ABSTRACT Raltegravir pharmacokinetics was studied in 20 patients included in the ANRS HC30 QUADRIH Study before and after addition of anti-hepatitis C virus (anti-HCV) quadritherapy, including pegylated-interferon–ribavirin and asunaprevir plus daclatasvir. Raltegravir pharmacokinetic parameters remained unchanged whether administered on or off anti-HCV therapy. In addition, concentrations of raltegravir, asunaprevir, and daclatasvir were not affected by liver cirrhosis. These data suggest that in human immunodeficiency virus (HIV)-HCV-coinfected patients, whether cirrhotic or not, asunaprevir and daclatasvir could be administered safely with raltegravir.

AdultLiver CirrhosisMaleDaclatasvirPyrrolidinesAlpha interferonHIV InfectionsHepacivirusPharmacologyAntiviral AgentsRaltegravir PotassiumPolyethylene Glycolschemistry.chemical_compoundPharmacokineticsRaltegravir PotassiumRibavirinMedicineHumansPharmacology (medical)PharmacologySulfonamidesbusiness.industryCoinfectionRibavirinImidazolesvirus diseasesInterferon-alphaValineHepatitis CHepatitis C ChronicMiddle AgedRaltegravirmedicine.diseaseIsoquinolinesdigestive system diseasesRecombinant ProteinsInfectious DiseaseschemistryLiverHIV-1AsunaprevirDrug Therapy CombinationFemaleCarbamatesbusinessmedicine.drugAntimicrobial agents and chemotherapy
researchProduct

High Cure Rate With 24 Weeks of Daclatasvir-Based Quadruple Therapy in Treatment-Experienced, Null-Responder Patients With HIV/Hepatitis C Virus Geno…

2015

BACKGROUND Few direct anti-hepatitis C virus (HCV) agents have been studied in difficult-to-treat null responder and cirrhotic human immunodeficiency virus (HIV)-coinfected patients. Daclatasvir and asunaprevir combined with pegylated interferon/ribavirin (peg-IFN/RBV) have shown promising results in HCV-monoinfected patients. METHODS An open-label, single-arm, phase 2 study was conducted in HIV/HCV genotype 1/4-coinfected patients who were null responders to prior peg-IFN/RBV standard therapy and on a raltegravir-based regimen with HIV RNA <400 copies/mL. They received a 4-week lead-in phase with peg-IFN/RBV, followed by 24 weeks of asunaprevir (100 mg twice daily), daclatasvir (60 mg once…

MaleMicrobiology (medical)medicine.medical_specialtyPyrrolidinesDaclatasvir[SDV]Life Sciences [q-bio]PopulationHIV InfectionsHepacivirusAntiviral AgentsGastroenterologychemistry.chemical_compoundPegylated interferonInternal medicinemedicineHumansdaclatasvireducationasunaprevireducation.field_of_study[ SDV ] Life Sciences [q-bio]Coinfectionbusiness.industryRibavirincirrhosisImidazolesvirus diseasesHIVValineHepatitis C ChronicMiddle AgedRaltegravirmedicine.disease3. Good healthRegimenTreatment OutcomeInfectious DiseaseschemistryImmunologyHCVCoinfectionAsunaprevirFemaleCarbamatesbusinessmedicine.drug
researchProduct